Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St. Jude Medical’s single-connector lead is approved

This article was originally published in The Gray Sheet

Executive Summary

FDA approves the first "four-pole" defibrillator connector system, allowing a single connection between a cardiac resynchronization therapy defibrillator (CRT-D) and its leads with one set screw, St. Jude announces Feb. 5. Traditional lead designs require three connections and four set screws. The new connector, known as IS-4 and also being developed by Medtronic and Boston Scientific, is meant to simplify surgical placement and provide a smaller product. St. Jude's "SJ4" system uses a Durata defibrillation lead and Promote CRT-D with SJ4 connectors. The firm will conduct a five-year post-approval study with up to 1,700 patients and gather additional data through its SCORE patient registry. Critics have called for greater pre-market human testing of such innovative lead designs for the sake of patient safety (1"The Gray Sheet" Dec. 15, 2008, p. 7)

You may also be interested in...



A Leading Question: When Is Human Testing Needed For ICD Approval?

Debate is surfacing in the medical and regulatory community over when clinical data is needed to approve new implantable cardioverter defibrillator technology

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.

Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector

With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027092

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel